1492 Capital Management LLC decreased its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 18.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,349 shares of the specialty pharmaceutical company’s stock after selling 8,018 shares during the period. ANI Pharmaceuticals accounts for about 1.8% of 1492 Capital Management LLC’s holdings, making the stock its 23rd biggest position. 1492 Capital Management LLC owned 0.30% of ANI Pharmaceuticals worth $2,278,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of ANI Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after purchasing an additional 35,722 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 25.2% in the third quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock worth $22,297,000 after purchasing an additional 85,529 shares in the last quarter. Deutsche Bank AG increased its stake in shares of ANI Pharmaceuticals by 7.4% in the fourth quarter. Deutsche Bank AG now owns 159,957 shares of the specialty pharmaceutical company’s stock worth $10,308,000 after purchasing an additional 10,982 shares in the last quarter. Northern Trust Corp increased its stake in shares of ANI Pharmaceuticals by 5.2% in the second quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock worth $5,285,000 after purchasing an additional 5,599 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of ANI Pharmaceuticals by 868.2% in the third quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock worth $5,404,000 after purchasing an additional 94,002 shares in the last quarter. Hedge funds and other institutional investors own 55.95% of the company’s stock.
In other news, SVP James G. Marken sold 4,177 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $61.92, for a total value of $258,639.84. Following the completion of the transaction, the senior vice president now directly owns 66,439 shares in the company, valued at $4,113,902.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Tracy Marshbanks sold 15,391 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $63.08, for a total transaction of $970,864.28. The disclosure for this sale can be found here. Insiders sold 112,441 shares of company stock valued at $7,044,036 over the last 90 days. 31.80% of the stock is owned by company insiders.
ANI Pharmaceuticals Inc (NASDAQ:ANIP) opened at $62.75 on Tuesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39. ANI Pharmaceuticals Inc has a 1 year low of $42.23 and a 1 year high of $74.70. The company has a market cap of $730.60, a P/E ratio of 59.20 and a beta of 2.75.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.06. ANI Pharmaceuticals had a negative net margin of 0.61% and a positive return on equity of 23.41%. The company had revenue of $47.30 million during the quarter, compared to analyst estimates of $52.55 million. During the same period last year, the business earned $0.84 earnings per share. ANI Pharmaceuticals’s revenue was up 23.8% compared to the same quarter last year. analysts predict that ANI Pharmaceuticals Inc will post 5.17 EPS for the current fiscal year.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.